Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: Stable gene transfer, regulated gene expression and therapeutic efficacy

Journal of Gene Medicine

Volumn 9, Issue 10, 2007, Pages 862-874

  Lamartina, Stefania ^a   Cimino, Monica ^b   Roscilli, Giuseppe ^a   Dammassa, Ernesta ^a   Lazzaro, Domenico ^a   Rota, Rossella ^c   Ciliberto, Gennaro ^a   Toniatti, Carlo ^a  

^a IRBM   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Helper dependent Adenovirus; Retinopathy; sFlt 1; Transcriptional regulation

Indexed keywords

ADENOVIRUS VECTOR; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENIC GENE THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETIC STABILITY; HELPER VIRUS; LONGEVITY; MUELLER CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RAT; RETINA NEOVASCULARIZATION; SPRAGUE DAWLEY RAT; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANOXIA; DOXYCYCLINE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELPER VIRUSES; HUMANS; MICE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ADENOVIRIDAE; CYTOMEGALOVIRUS; MUS; RATTUS;

EID: 35148861116     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1083     Document Type: Article

References (71)

1. Bennet J, Maguire AM. Gene therapy for ocular disease. Mol. Ther 2000; 1: 501-505.
2. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. Gene Ther 2006; 13: 1191-1197. DOI: 10.1038/ sj.gt.3302812.
3. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. Br Med J 2003; 326: 485-488.
4. Frank R. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
5. Campochiaro P. Ocular neovascularization and excessive vascular permeability. Expert Opin Biol Ther 2004; 4: 1395-1402. DOI: 10.1517/14712598.4.9.1395.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
7. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438: 960-966.
8. Kulkarni AD. Wet age-related macular degeneration. Adv Drug Deliv Rev 2005; 57: 1994-2009. DOI: 10.1016/j.addr.2005.09.003.
9. Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005; 21: 1544-1550. DOI: 10.1038/sj.gt.3302579.
10. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9. DOI: 10.1016/j.ajo.2006.02.037.
11. Ng EWM, Shime DT, Calias P, et al. Pegatanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132. DOI: 10.1038/nrd1955.
12. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophtalmology 2006; 113: 633-642. DOI: 10.1016/j.ophtha.2006.01.027.
13. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targteting VEGF receptor 1. Gene Ther 2006; 13: 559-562.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816. DOI: 10.1056/NEJMoa042760.
15. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. J Am Med Assn 2005; 293: 1509-1513.
16. Reich SJ, Bennett J. Gene therapy for ocular neovascularization: a cure in sight. Curr Opin Genet Dev 2003; 13: 317-322.
17. Toniatti C, Bujard H, Cortese R, Cilberto G. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 2004; 11: 649-657.
18. McFarland TJ, Zhang Y, Appukuttan B, et al. Gene therapy for proliferative ocular diseases. Expert Opin Biol Ther 2004; 4: 1053-1058. DOI: 10.1517/14712598.4.7.1053.
19. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15: 1022-1033. DOI: 10.1089/1043034042431119.
20. Bessis N, GarciaCozar FJ, Boissier MC. Immune response to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11: 10-17. DOI: 10.1038/sj.gt.3302364.
21. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003; 10: 977-982.
22. Mori K, Gehlbach P, Ando A, et al. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. Invest Ophthalmol Vis Sci 2002; 43: 1610-1615.
23. Anzai K, Yoneya S, Gehlbach PL, et al. Laser photocoagulation and, to a lesser extent, photodynamic therapy target and enhance adenovirus vector-mediated gene transfer in the rat retina. Invest Ophthalmol Vis Sci 2005; 46: 3883-3891. DOI: 10.1167/iovs.05-0593.
24. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 2005; 16: 1-16.
25. Muruve DA, Cotter MJ, Zaiss AK, et al. Helper-dependent adenovirus vectors elicit innate but attenuated adaptative host immune response in vivo. J. Virol 2004; 78: 5966-5972.
26. Brunetti-Pierri N, Nichols TC, McCorquodale S, et al. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 2005; 16: 811-820. DOI: 10.1089/hum.2005.16.811.
27. Brunetti-Pierri N, Ng T, Iannitti DA, et al. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 2006; 17: 391-404. DOI: 10.1089/hum.2006.17.391.
28. Keriel A, Rene C, Galer C, et al. Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J Virol 2006; 80: 1487-1496. DOI: 10.1128/JVI.80.3.1487-1496.2006.
29. Giampaoli S, Nicolaus G, Delmastro P, Cortese R. Adeno-cosmid cloning vectors for regulated gene expression. J Gene Med 2002; 4: 490-497.
30. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-10709.
31. kid-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol Ther 2003; 7: 271-280.
32. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000; 97: 1002-1007.
33. Davis JL, Cilger BC, Robinson MR. Novel approaches to ocular drug delivery. Curr Opin Mol Ther 2004; 6: 195-205.
34. Ng P, Parks RJ, Graham FL. Preparation of helper-dependent adenoviral vector. Methods Mol Med 2002; 69: 371-388.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 - ΔΔCT method. Methods 2001; 25: 402-408.
36. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Müller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci U S A 1998; 95: 3978-3983.
37. Gauthier R, Joly S, Pernet V, et al. Brain-derived neurotrophic factor gene delivery to muller glia preserves structure and function of light-damaged photoreceptors. Invest Ophthalmol Vis Sci 2005; 46: 3383-3392. DOI: 10.1167/iovs.05-0362.
38. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene 2003; 22: 6537-6548. DOI: 10.1038/ sj.onc.1206773.
39. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328.
40. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci 1995; 36: 2063-2070.
41. Mansui IM, Bujard H. Tetracycline-regulated gene expression in the brain. Curr Opin Neurobiol 2000; 10: 593-596. DOI: 10.1016/ S0959-4388(00)00 127-6.
42. Lai YK, Shen WY, Brankov M, et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 9: 804-813. DOI: 10.1038/sj/gt/3 301 695.
43. Lai CM, Shen WY, Brankov M, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 2005; 12: 659-668. DOI: 10.1016/ j.ymthe.2005.04.022.
44. Kreppel F, Luther TT, Semkova I, et al. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector. Invest Ophthalmol Vis Sci 2002; 43: 1965-1970.
45. Chao TI, Grosche J, Friedrich KJ, et al. Comparative studies on mammalian Muller (retinal glial) cells. J Neurocytol 1997; 26: 439-454. DOI: 10.1023/A:1018 525 222 826.
46. Famiglietti EV, Stopa EG, McGookin ED, et al. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003; 969: 195-204. DOI: 10.1016/S0006-8993(02)03 766-6.
47. Newman E, Reichenbach A. The Müller cell: a functional element of the retina. Trends Neurosci 1996; 19: 307-312.
48. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909. DOI: 10.1073/pnas.92.3.905.
49. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of phase I clinical trial. Hum Gene Ther 2006; 17: 167-176.
50. Lebherz C, Maguire AM, Auricchio A, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 2005; 54: 1141-1149.
51. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-10461.
52. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996; 93: 4851-4856.
53. Wegewitz U. Novel approaches in the treatment of angiogenic eye disease. Curr Pharm Des 2005; 11: 2311-2330. DOI: 10.2174/1 381 612 054 367 292.
54. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156: 697-707.
55. Comer GM, Ciulla TA. Current and future pharmacological intervention for diabetic retinopathy. Expert Opin Emerg Drugs 2005; 10: 441-455.
56. Kinose F, Roscilli G, Lamartina S, et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis 2005; 11: 366-373.
57. Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002; 9: 320-326.
58. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 2003; 14: 129-141. DOI: 10.1089/104 303 403 321 070 829.
59. Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1-gene transfer. J Gene Med 2004; 6: 992-1022. DOI: 10.1002 /jgm.586.
60. Salucci V, Scarito A, Aurisicchio L, et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 2002; 9: 1415-1421. DOI: 10.1038/sj.gt.3301813.
61. Latta-Mahieu M, Rolland M, Caillet C, et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620. DOI: 10.1089/10 430 340 260 201 707.
62. Favre D, Blouin V, Provost N, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76: 11605-11611. DOI: 10.1128/ JVI.76.22.11605-11611.2002.
63. Ginhoux F, Turbant S, Gross DA, et al. HLA-A*0201-restricted cytolytic responses to the rtA transactivator dominant and cryptic epitopes compromises transgene expression induced by the tetracycline on system. Mol Ther 2004; 10: 279-289.
64. Stieger K, Le Meur G, Lasne F, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006; 13: 967-975. DOI: 10.1016 /j.ymthe.2005.12.001.
65. Lebherz C, Auricchio A, Maguire AM, et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther 2005; 16: 178-186.
66. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004; 48: 1045-1058.
67. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
68. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188: 253-263. DOI: 10.1002/jcp.1114.
69. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490-494.
70. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
71. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-2434.